E

Elanco

Global animal health pharmaceutical company

R&D Project Manager

Full-TimeUpdated on 10/23/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Indianapolis, IN, USA
HybridHybrid work environment; travel up to 10% annually.
Project & Program ManagementProject Management

About the job

Requirements
  • A Bachelor's or Master's degree in a scientific or related field and 8–10 years of relevant experience in project management or a related scientific role.
  • A deep understanding of the veterinary drug development process and the interdependencies of tasks requiring coordination among global teams, functional groups, and third parties.
  • Demonstrated experience with regulatory submission processes and requirements, and a strong grasp of Good Clinical Practice, Good Laboratory Practice, and Good Manufacturing Practice quality principles.
  • Mastery of project management fundamentals and processes defined by the Project Management Body of Knowledge (PMBOK).
  • Technical proficiency with project management software, the Microsoft Office Suite, and emerging artificial intelligence platforms.
  • Ability to influence without direct authority and guide global, cross-functional teams through complex and ambiguous situations.
  • Interpersonal and team-building skills, with the ability to develop effective teams with diverse interpersonal styles and deliver coaching and feedback.
  • A proactive approach to problem-solving, with the ability to anticipate and recognize systemic problems, diagnose root causes, and take corrective action to prevent recurrence.
  • Ability to demonstrate flexibility and adjust effectively to frequent change and altered priorities.
Responsibilities
  • Act as a strategic partner to project leaders by independently managing project management activities for complex, high-impact development programs.
  • Guide deliverable execution by managing schedules, costs, and performance risks; facilitate scenario planning to develop realistic milestones; and maintain scope documentation aligned with strategic goals.
  • Own project plans, develop and maintain timelines and process maps, identify and communicate the critical path and leading indicators of progress, monitor performance against plan, and guide team action to keep projects on track while ensuring data completeness and quality across systems.
  • Partner with Finance, functional areas, and geographies to manage the team's development budget; report and explain variances, drive re-forecasts, update budget data in appropriate tools, and clarify the costs of development options.
  • Guide development-risk assessment and establish mitigation and contingency plans with clear ownership; communicate risks affecting the critical path and trigger contingency plans to avoid or mitigate those risks.
  • Promote continuous improvement by generating process ideas and sharing learnings with the team and function; identify ways to improve effectiveness, decrease development cycle times, and consistently apply project-management tools and concepts to maximize business value.
Desired Qualifications
  • PMP or CAPM certification.
  • Direct experience in the Animal Health industry.
  • A growth mindset and curiosity, with eagerness to ask questions and learn rapidly.
  • Ability to work effectively independently and collaboratively.

About the company

Elanco is a global animal health company that develops medicines, vaccines, and preventive care products for livestock and pets. Its products include prescription medicines, vaccines, and parasite-control solutions used by veterinarians, farmers, and pet owners to protect animal health and welfare and improve productivity. After separating from Eli Lilly in 2019, Elanco expanded its scale by acquiring Bayer Animal Health in 2020, which broadened its reach in the companion-animal market and added direct-to-consumer capabilities. Its goal is to advance animal health and welfare worldwide by providing effective, accessible products and services while growing sustainably as a standalone company.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1954

Get referred to Elanco

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 Q2 revenue reached $1.368 billion, with 8% organic constant-currency growth.
  • August 26, 2026 Elwood expansion quadrupled mAb capacity, supporting Befrena and Trutect.
  • Elanco raised 2026 innovation revenue to $1.25 billion and targets unconstrained Befrena supply by early 2027.

What critics are saying

  • December 2025 restructuring hit 600 roles and $175 million charges, with closures continuing through 2026.
  • Seventh Circuit affirmed Elanco's securities case on August 14, 2026, keeping disclosure risk alive.
  • Befrena demand is twice expectations; any manufacturing or safety setback would cripple Elanco's biologics thesis.

What makes Elanco unique

  • Elanco owns one of two animal-health monoclonal antibody platforms, centered in Elwood, Kansas.
  • Befrena and Trutect give Elanco proprietary biologics manufacturing control, not outsourced dependence.
  • Elanco spans farm and pet health, unlike narrower companion-animal rivals like Zoetis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • 401(k) Company Match
  • Parental Leave
  • Annual Bonus
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

5%

1 year growth

5%

2 year growth

5%
PR Newswire
Oct 22nd, 2026
Elanco names Eli Lilly's Jamie Preston chief people officer as Dave Kinard retires

Elanco Animal Health has appointed Jamie Preston as executive vice president and chief people officer, effective November 3. She succeeds Dave Kinard, who plans to retire at the end of the year and will help with the transition. Preston joins from Eli Lilly and Company, where she spent 23 years. Most recently she was vice president of HR, global compensation and workforce innovation, leading compensation for an organisation of more than 50,000 employees. "Jamie is a visionary, dynamic leader with the speed and agility that defines Elanco," said chief executive officer Jeff Simmons. Simmons said employee engagement is the highest since Elanco's IPO, crediting Kinard's leadership. Kinard also oversaw the move of the company's headquarters from Greenfield to Indianapolis.

WBIW
Oct 15th, 2026
Purdue, Elanco break ground on new One Health Research Institute in Indianapolis.

Purdue, Elanco break ground on new One Health Research Institute in Indianapolis. October 15, 2026 INDIANAPOLIS - Purdue University and Elanco Animal Health have broken ground on a new research facility designed to advance health solutions for people, animals, plants and the environment. University, industry and government leaders gathered Tuesday, Oct. 6, to mark the beginning of construction on the One Health Research Institute, part of the developing One Health Innovation District near downtown Indianapolis. The planned 150,000-square-foot facility will feature advanced research laboratories, shared equipment and research infrastructure, business incubator space, collaboration areas and facilities supporting animal health and veterinary partners. Purdue will serve as the institute's academic and research anchor, connecting faculty, students and researchers with industry partners and entrepreneurs. Elanco will contribute its animal health expertise and scientific resources while helping connect research discoveries with the development and commercialization of new solutions. The institute is intended to encourage collaboration across scientific disciplines, recognizing that human, animal, plant and environmental health are interconnected. Purdue Interim President Mitch Daniels said the project supports the university's land-grant mission while expanding its presence in Indianapolis and contributing to Indiana's economic growth. The institute is expected to create opportunities for research partnerships and innovation that could help address complex health challenges.

Feed and Additive
Oct 14th, 2026
NOVUS appoints two sales managers in Indonesia.

NOVUS appoints two sales managers in Indonesia. 14 October 2026 NOVUS has appointed veterinarians Hendri Ahadianto and Lucia Simanjuntak as sales managers in Indonesia. Based in Jakarta, they will work with customers across the country on animal health, nutrition and feed-related challenges. NOVUS has expanded its commercial team in Indonesia with the appointment of veterinarians Hendri Ahadianto and Lucia Simanjuntak as sales managers. Based in Jakarta, Ahadianto and Simanjuntak work with customers throughout Indonesia, bringing experience in animal health, nutrition, feed additives, customer relationship management and technical evaluation. According to NOVUS, their expertise strengthens the company's ability to collaborate with feed mills, integrators, nutritionists and producers as poultry, swine and dairy customers navigate changing feed costs, raw-material variability and other production challenges. Simanjuntak's expertise includes poultry nutrition and health, feed additive formulation, intestinal health risk management, and evaluating the technical and economic benefits of nutrition programs. She works with customers to connect feed mill considerations with farm performance through formulation assessment, field trials, performance data and return-on-investment analysis. "What I enjoy most is solving practical customer problems and seeing the results in the field," says Lucia Simanjuntak. "Indonesia's animal agriculture industry faces changing feed ingredients, production pressures and animal health challenges, so continuous learning and strong customer relationships are essential. I look forward to combining technical knowledge with NOVUS resources to help customers develop practical feeding programs that deliver measurable value." Ahadianto brings nearly 20 years of animal health industry experience, with a background in communication, leadership and relationship building. In his role, he combines those skills with business analysis to understand customers' challenges and identify practical options for their operations. "After many years in animal health, joining NOVUS gives me an opportunity to take on a new challenge and expand my experience in animal nutrition," Hendri Ahadianto says. "Building close relationships is important to me. I want to understand each customer's business and work alongside them to find practical solutions to the challenges they face." Rika Riantika, Senior Regional Sales Manager at NOVUS, says the different backgrounds of her two newest colleagues strengthen the support NOVUS can provide customers in Indonesia. "Lucia and Hendri bring valuable but complementary experience to our team," says Riantika. "Hendri's extensive animal health background, business perspective and ability to build strong customer relationships pair well with Lucia's experience in animal health, nutrition solutions and technical evaluation. Together, they strengthen our ability to understand what customers are facing and connect them with the expertise and resources available through NOVUS." Before joining NOVUS, Lucia Simanjuntak served as sales manager for western Indonesia with Huvepharma Animal Health Indonesia. She also served as business manager for western Indonesia with Evonik Indonesia. Simanjuntak earned her doctorate in veterinary medicine from Gadjah Mada University in Yogyakarta, Indonesia. Hendri Ahadianto previously served as a strategic account manager with Elanco Animal Health. He also held sales and technical roles with Zoetis, Pfizer Animal Health, and Romindo Primavetcom. He earned his veterinary degree from Airlangga University in Surabaya, Indonesia.

RB Magazine
Oct 1st, 2026
Beef specialist joins Elanco's southern team.

Beef specialist joins Elanco's southern team. Leading animal health company, Elanco, has announced the appointment of Claire Scott as its new territory manager for southern NSW and Riverina. Claire brings almost a decade's experience in beef production via previous roles with a leading Angus stud in southern NSW and an integrated grazing, lot feeding and cropping operation in WA. "With practical experience and technical knowledge in beef production, nutrition, genetics and data-based performance systems, Claire is a great asset for our southern farm animal team," Elanco farm animal business unit head, Jamie Dowsley, says "She also has a keen interest in animal health and welfare, having spent four years as a veterinary nurse at two veterinary practices in Perth, WA. "Claire has proven herself to be extremely confident working with livestock producers and their advisors to develop practical programs that improve animal health, productivity and operations." Claire holds a Bachelor of Science (Veterinary Nursing) from Letterkenny Institute of Technology, Ireland, as well as Level IV certificates in Agriculture and Work Health & Safety. More recently, she has completed the Marcus Oldham Rural Leadership Program and Rabobank Farm Managers P rogram. Reporting to Regional Sales Manager - South, Mark McLennan, Claire joins other five other Territory Managers in Elanco's southern team: Alice Lewis (Southern NSW), Jas Marshall (Central Victoria), Colin Andrews (SE South Australia & West Vic), Brent Burgess (Tasmania/Gippsland) and Wayne Clonan (Northern SA, Broken Hill & Sunraysia).

Feedstuffs
Sep 18th, 2026
Bimeda USA expands anti-parasitic line for cattle.

Bimeda USA expands anti-parasitic line for cattle. Moxisolv Pour-On is an FDA-approved bioequivalent option containing 0.5% moxidectin. September 18, 2026 Bimeda is expanding its anti-parasitic portfolio with MoxiSolv Pour-On (moxidectin), initially available in 5 L and 10 L sizes for cattle producers. Bimeda is pleased to announce the expansion of its anti-parasitic portfolio with the addition of MoxiSolv(TM) Pour-On (moxidectin). MoxiSolv Pour-On is the first available Food & Drug Administration-approved, bioequivalent alternative to Cydectin(R) Pour-On (moxidectin) by Elanco and is initially available in 5 L and 10 L sizes for producers. MoxiSolv Pour-On is a ready-to-use topical parasiticide containing 0.5% moxidectin and is labeled for use in beef and dairy cattle of all ages, including lactating dairy cows. It provides treatment and control of gastrointestinal roundworms, lungworms, cattle grubs, mites, lice and horn flies. Moxidectin pour-on products offer a zero-day milk withdrawal and a short pre-slaughter withdrawal time, giving producers flexibility compared to pour-on products that carry longer withdrawal periods. MoxiSolv Pour-On features a purple dye for visible application and is formulated for consistent pour and absorption across the hide. It is manufactured in the U.S. under strict quality standards and offers producers a trusted bioequivalent option in a familiar pour-on format. A unique benefit of moxidectin is that it is dung-beetle friendly. Healthy dung beetle populations have been shown to play a key role in maintaining soil health in pastures, and they also aid producers' efforts in controlling internal and external parasites. As dung beetles disperse manure, they reduce breeding environments for horn flies and limit further exposure to gastrointestinal nematodes. Dr. Eric Moore, DVM, head of technical services North America at Bimeda, said, "Producers continue to look for parasite control solutions that balance efficacy, safety and environmental stewardship. MoxiSolv Pour-On delivers reliable moxidectin performance in a convenient pour-on format while supporting dung beetle populations that contribute to healthier pastures. It's a product that aligns with both animal health and long-term sustainability goals." Feedstuffs is the news source for animal agriculture